



- (51) **International Patent Classification:**
A01N 43/04 (2006.01) *A61K 31/715* (2006.01)
- (21) **International Application Number:**
PCT/US2012/040247
- (22) **International Filing Date:**
31 May 2012 (31.05.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/491,773 31 May 2011 (31.05.2011) US
- (71) **Applicant (for all designated States except US):** **REGENTS OF THE UNIVERSITY OF MINNESOTA** [US/US]; Office for Technology Commercialization, 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114-8658 (US).
- (72) **Inventors; and**
- (71) **Applicants :** **HOYE, Thomas R.** [US/US]; c/o Regents of the University of Minnesota, 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114-8658 (US). **WOHL, Adam** [US/US]; c/o Regents of the University of Minnesota, 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114-8658 (US). **MACOSKO, Christopher W.** [US/US]; c/o Regents of the University of Minnesota, 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114-8658 (US). **PANYAM, Jayanth** [US/US]; c/o Regents of the University of Minnesota, 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114-8658 (US).
- (74) **Agents:** **HARRIS, Robert J.** et al.; Viksnins Harris & Padys PLLP, 7900 International Drive, Suite 670, Bloomington, Minnesota 55425 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** SILICATE PRODRUGS AND NANOPARTICLES

(57) **Abstract:** The invention provides silicate prodrugs comprising a therapeutic agent linked to one or more groups of formula (I): $-\text{Si}(\text{OR})_3$ (I); wherein each R independently has any of the values defined herein, as well as nanoparticles comprising such compounds.



SILICATE PRODRUGS AND NANOPARTICLES

Priority of Invention

The application claims priority to United States Provisional Application Number 61/491,773, filed 31 May 2011. The entire content of this provisional application is hereby
5 incorporated by reference herein.

Background of the Invention

The use and effectiveness of many therapeutic agents is limited by the solubility of the agents. Taxanes like paclitaxel and docetaxel are chemotherapy agents that are commonly used in the treatment of breast, lung, prostate and other cancers. Taxanes interfere with the microtubules in
10 the cancer cell, stopping the cell from dividing and causing its death. Unfortunately, the use and effectiveness of taxanes is limited by the solubility of the agents.

Taxol[®] and Taxotere[®], two leading cancer therapeutics, are formulations of the minimally water-soluble antitumor agents paclitaxel (PTX) and docetaxel (DTX), respectively, solubilized in the adjuvants Cremophor EL[®] and polysorbate 80 (Tween 80[®]), respectively. However, Taxol[®] and
15 Taxotere[®] contain only about 1 and 4 wt%, respectively, of the actives. The large amount of the surfactant/excipient/carrier that accompanies drug dosage leads to a range of undesirable side effects. For example, many patients show acute hypersensitivity response to Cremophor EL[®] present in Taxol[®]; 1.5-3% suffer major, potentially life-threatening reactions. Abraxane[®] is an alternative formulation of PTX in which a “human albumin-stabilized, lyophilized NP formulation”
20 is used instead of Cremophor EL[®]. Abraxane[®] contains *ca.* 10 wt% PTX, and is approved only for second-line metastatic breast cancer patients. Clearly there is a need for developing improved formulations for taxane (and other similarly hydrophobic) antitumor agents.

There is currently a need for methods to modify the solubility of certain therapeutic agents to improve their ability to be administered as therapeutics. There is also a need for new
25 formulations and for formulating methods that can be used to deliver therapeutic agents to patients. In particular, there is a need for formulations that have higher drug loading (i.e., less excipient), that can be localized preferentially at a tumor site, or that selectively release their drug payload in the environment (e.g. more acidic) of the tumor.


Summary of the Invention

30 Applicant has discovered that silicate ester derivatives of drugs [e.g., DRUG-O-Si(OR)₃, wherein each R can be the same or different] can function as prodrugs. The silicate moiety can be

09531.308WO1 - 20110152

tailored to dictate, independently, both the hydrophobicity of the prodrug as well as its rate of hydrolysis. Additionally, Applicant has discovered that these silicate prodrugs can be co-precipitated with biocompatible block copolymers (BCPs), using flash nanoprecipitation (FNP), to produce nanoparticles (NPs) in a size regime ideal for exploiting the enhanced permeation and retention (EPR) effect (e.g. about 100 nm diameter) for localization of particles at solid tumor sites.

Accordingly there is provided a compound of the invention which is a compound comprising a therapeutic agent linked to one or more (e.g. 1, 2, 3, or 4) groups of formula (I):



wherein:

each R is independently selected from (C₁-C₂₀)alkyl, (C₂-C₂₀)alkenyl, (C₂-C₂₀)alkynyl, (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, and (C₂-C₂₀)alkynylcarbonyl, wherein each (C₁-C₂₀)alkyl, (C₂-C₂₀)alkenyl, (C₂-C₂₀)alkynyl, (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, and (C₂-C₂₀)alkynylcarbonyl, is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl.

The invention also provides a formulation comprising a compound of the invention and a PEG-*b*-PLGA block co-polymer.

The invention also provides a nano-particle comprising a compound of the invention and a PEG-*b*-PLGA block co-polymer.

The invention also provides a method to treat cancer in an animal (e.g. a human) comprising administering a compound of the invention or a formulation of the invention to the animal.

The invention also provides a compound of the invention or a formulation of the invention for use in medical therapy.

The invention also provides a compound of the invention or a formulation of the invention for the prophylactic or therapeutic treatment of cancer.

The invention also provides the use of a compound of the invention or a formulation of the invention to prepare a medicament for treating cancer in an animal (e.g. a human).

The invention also provides processes and intermediates disclosed herein that are useful for preparing compounds or formulations of the invention.

The prodrugs and formulations of the invention have a number of useful advantages. For example, certain formulations of the invention have higher drug loading (e.g. less excipient), can be

09531.308WO1 - 20110152

localized preferentially at a tumor site, or selectively release their drug payload in the environment (e.g. more acidic) of the tumor.

Brief Description of the Figures

FIG. 1 Illustrates release data for representative compounds of formula (I) from Example 10.

FIG. 2 Illustrates anticancer efficacy for representative compounds of formula (I) from Example 11.

FIG. 3 Illustrates data for a representative compound of formula (I) from Example 12.

FIG. 4 Illustrates the preparation of representative compounds of the invention.

FIG. 5 Illustrates mean luminescence quantitation measured in Example 16.

Detailed Description

The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as propyl embraces only the straight chain radical, a branched chain isomer such as isopropyl being specifically referred to. (C₂-C₂₀)Alkenyl is a (C₂-C₂₀)alkyl chain having one or more double bonds in the chain. (C₂-C₂₀)Alkynyl is a (C₂-C₂₀)alkyl chain having one or more triple bonds and optionally one or more double bonds in the chain. (C₁-C₂₀)alkanoyl is (C₁-C₁₉)alkylC(=O)-. (C₂-C₂₀)Alkenylcarbonyl is (C₂-C₂₀)alkenylC(=O)-. (C₂-C₂₀)Alkynylcarbonyl is (C₂-C₂₀)alkynylC(=O)-. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.

It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).

Specific values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

09531.308WO1 - 20110152

Specifically, (C₁-C₂₀)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; (C₁-C₆)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy; (C₂-C₂₀)alkenyl can be vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl; (C₂-C₂₀)alkynyl can be ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 1-pentylnyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl; (C₁-C₂₀)alkanoyl can be acetyl, propanoyl or butanoyl; and aryl can be phenyl, indenyl, or naphthyl.

In one embodiment of the invention an oxygen of a hydroxy group of the therapeutic agent is linked to the group of formula (I).

In one embodiment of the invention each R is independently selected from (C₁₀-C₂₀)alkyl, (C₁₀-C₂₀)alkenyl, (C₁₀-C₂₀)alkynyl, (C₁₀-C₂₀)alkanoyl, (C₁₀-C₂₀)alkenylcarbonyl, (C₁₀-C₂₀)alkynylcarbonyl, wherein each (C₁₀-C₂₀)alkyl, (C₁₀-C₂₀)alkenyl, (C₁₀-C₂₀)alkynyl, (C₁₀-C₂₀)alkanoyl, (C₁₀-C₂₀)alkenylcarbonyl, (C₁₀-C₂₀)alkynylcarbonyl, is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl.

In one embodiment of the invention each R is independently selected from (C₅-C₂₀)alkyl, (C₅-C₂₀)alkenyl, (C₅-C₂₀)alkynyl, (C₅-C₂₀)alkanoyl, (C₅-C₂₀)alkenylcarbonyl, (C₅-C₂₀)alkynylcarbonyl, wherein each (C₅-C₂₀)alkyl, (C₅-C₂₀)alkenyl, (C₅-C₂₀)alkynyl, (C₅-C₂₀)alkanoyl, (C₅-C₂₀)alkenylcarbonyl, (C₅-C₂₀)alkynylcarbonyl, is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl.

In one embodiment of the invention oxygens of at least two (e.g. 1, 2, or 3) hydroxy groups of the therapeutic agent are linked to groups of formula (I).

In one embodiment of the invention each R is independently selected from (C₁-C₂₀)alkyl, (C₂-C₂₀)alkenyl, and (C₂-C₂₀)alkynyl, wherein each (C₁-C₂₀)alkyl, (C₂-C₂₀)alkenyl, and (C₂-C₂₀)alkynyl is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl.

In one embodiment of the invention each R is independently selected from (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, (C₂-C₂₀)alkynylcarbonyl, wherein each (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, (C₂-C₂₀)alkynylcarbonyl, is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl.

In one embodiment of the invention at least one R is independently selected from (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, (C₂-C₂₀)alkynylcarbonyl, wherein each (C₁-C₂₀)alkanoyl,


09531.308WO1 - 20110152

(C₂-C₂₀)alkenylcarbonyl, (C₂-C₂₀)alkynylcarbonyl, is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl.

In one embodiment of the invention the therapeutic agent is a taxane.

In one embodiment of the invention the therapeutic agent is a paclitaxel or docetaxel.


5 In one embodiment the invention provides a compound of formula (Ia):



wherein R¹ is a group of formula (I), or a salt thereof.

In one embodiment of the invention provides a compound of formula (Ib):


10



wherein R¹ and R² are each independently a group of formula (I), or a salt thereof.

In one embodiment of the invention provides a compound of formula (Ic):


09531.308WO1 - 20110152



(Ic)

wherein R³ is a group of formula (I), or a salt thereof.


In one embodiment of the invention provides a compound of formula (Id):



(Id)

wherein R² is a group of formula (I), or a salt thereof.







In one embodiment of the invention the compound of formula (I) is selected from:




1a

2a


09531.308WO1 - 20110152



09531.308WO1 - 20110152





and





and salts thereof.




In one embodiment of the invention provides a compound selected from:




5



09531.308WO1 - 20110152



and



and salts thereof.

- 5 Processes for preparing compounds of the invention are provided as further embodiments of the invention and are illustrated by the following procedures in which the meanings of the generic radicals are as given above unless otherwise qualified.

In cases where compounds are sufficiently basic or acidic, a salt of a compound of the invention can be useful as an intermediate for isolating or purifying a compound of the invention.

- 10 Additionally, administration of a compound of the invention as a pharmaceutically acceptable acid or base salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartrate, succinate, benzoate, ascorbate, α -ketoglutarate, and α -glycerophosphate. Suitable inorganic salts may also be formed, including
- 15 hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid

09531.308WO1 - 20110152

affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

The compounds of the invention can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.

Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.

The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.

The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water,

09531.308WO1 - 20110152

optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at

09531.308WO1 - 20110152

effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.

5 Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

10 Examples of useful dermatological compositions which can be used to deliver the compounds of the invention to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

15 Useful dosages of the compounds of the invention can be determined by comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

20 The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

25 The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

Nanoparticle Preparation

30 Nanoparticles of the invention can be prepared using well known methods, including multijet vortex mixing as described by Liu, Y., Cheng, C.Y., Liu, Y., Prud'homme, R.K., Fox, R.O., *Chem Eng Sci.* **2008**, 63, 2829-2842; impinging jet mixing as described by U.S. PPA 2004/0091546A1, Johnson, B.K. and Prud'homme, R.K., *AIChE Journal*, **2003**, 49, 9, 2264-2282 and Johnson, B.K. and Prud'homme, R.K., *Aust. J. Chem*, **2003**, 56, 1021-1024; and emulsion

09531.308WO1 - 20110152

methods as described by Patil YB, Toti US, Khdair A, Ma L, Panyam J., Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. *Biomaterials*. 2009 Feb;30(5):859-66.

Silicate prodrugs can be loaded *at high levels* (>50 wt% paclitaxel) into particles that will be stable in intravenous circulation, will accumulate in tumors, and will release paclitaxel to effectively inhibit tumor growth. Using an impingement jet mixer, an attempt was made to encapsulate unmodified paclitaxel. A solution of THF containing equal masses of PEG-*b*-PLGA and paclitaxel was impinged under turbulent mixing against an equal volume of water and the effluent immediately (<1 sec) diluted into water. The solvent ratio of the resulting NP suspension was 95:5 H₂O:THF. Dynamic light scattering (DLS) measurements of this suspension were recorded. Initially, the diameters of these loaded NPs were *ca.* 100 nm, but they proved to be unstable. Rapid Ostwald ripening ensued within 90 minutes; that is, paclitaxel left the NP core and reprecipitated, this time as large (>>1 μ m) crystals.

In contrast, the particles made from *equal masses* of the same BCP and the paclitaxel bis-triethyl silicate compound **2a** were also formed with small mass average diameters (d_m =150 nm), but were stable in suspension for at least 4 days (even in the presence of 1% NaCl). It appears that the presence of the two triethyl silicate groups in **2a** sufficiently increases the hydrophobicity of paclitaxel to slow Ostwald ripening.

In one embodiment of the invention the paclitaxel silicate prodrug will be sufficiently hydrophobic to be efficiently co-precipitated into a NP during FNP in order to achieve high loading levels of the taxane prodrug. The ideal prodrug will be identified by its manageable stability during preparation, purification, encapsulation, and formulation storage lifetime, yet its rate of hydrolysis at a tumor site will be pharmacologically effective. Since the prodrug solubility in water will be quite low, premature release of the prodrug from the NPs into the blood prior to localization of the loaded NPs at tumor sites can be expected to be minimal. The prodrug hydrophobicity can be modified using an array of safe aliphatic alcohols of increasing aliphatic character (*e.g.* ethanol, decanol, geraniol, and phytol) to prepare the requisite SiCl(OR)₃ reagents for synthesis of prodrug candidates.

The nanoparticles of the invention are particularly advantageous as potential therapeutic agents because i) they can be prepared in a size range (50-200 nm) that is attractive from the

09531.308WO1 - 20110152

perspective of enhanced permeation and retention (EPR) into and by solid tumors and ii) they can be formulated to comprise at least 50 wt% of the prodrug.

Synthesis of block copolymers.

It was determined that PEG-*b*-PLGA BCPs with *narrow polydispersity* ($PDI \leq 1.1$) could be prepared by DBU-catalyzed (1,8-diazabicyclo[5.4.0]undec-7-ene) ring-opening co-polymerization of lactide and glycolide using Me-PEG-OH as the initiator (Lohmeijer, B. G. G., et al., Guanidine and Amidine Organocatalysts for Ring-Opening Polymerization of Cyclic Esters. *Macromolecules* **2006**, 39, 8574–8583). The key to success here was controlled infusion of the more reactive glycolide monomer throughout the polymerization reaction. Notably, this approach allows i) the avoidance of toxic tin catalysts and ii) reliable preparation of a homologous series of related and well-defined BCPs for use in NP optimization studies. To understand and optimize their impact on the properties of silicate loaded NPs, a series of BCPs that vary in block size, block ratio, and glycolide:lactide ratio (within the random polyester hydrophobic block) can be made and assessed. Specifically, PEG-*b*-PLGAs of the following sizes: 5K/5K, 5K/10K, 5K/15K and 10K/5K, 10K/10K, 10K/20K can be prepared. Nanoparticles can be loaded and then assessed for controllability of NP size; efficiency of capturing silicate prodrug; stability upon freeze drying, resuspension in buffer, and storage; and hydrolysis/release behavior. For the best performing BCP, the effect of changing the glycolide:lactide composition within the PLGA from 50:50 (e.g. to 80:20) can be assessed.

A variety of block co-polymers can be used to prepare the formulations and nanoparticles of the invention. For example, any biocompatible block copolymer with a varying number of blocks can, in principle, be used. Typically the hydrophilic block will be a polyether and the hydrophobic block will be a polyester, polyamino acid, polyamine, polyimine, polyamide, polycarbonate, or polycarbamate, etc. Other hydrophobic blocks may include polyethylene, polystyrene, etc. Suitable block co-polymers can be prepared using any suitable method, including the methods described herein as well as the methods described by Afsaneh LaVasanifar, et al., *J. Pharmaceutical Sciences*, 2003, 92, no. 7; and Omathanu Pillai and Ramesh Panchagnula, *Current Opinion in Chemical Biology*, **2001**, 5, issue 4, pages 447-451.

09531.308WO1 - 20110152

Therapeutic Agents.

In principle, any drug with a derivatizable hydroxyl group can be modified with an electrophilic silylating agent, such as a trialkoxychlorosilane, resulting in a silicate ester prodrug. Hydrolytic cleavage catalyzed by a weak acid returns the parent drug. It should be noted that a number of studies imply that orthosilicic acid [Si(OH)₄], the byproduct of this prodrug cleavage, should not impose a significant health risk (see Gitelman HJ, et al., *Kidney Int*, **1992**, 42:957–959; and Marco-Franco JE, et al., **1991**, *Clin Nephrol*, 35:52–58).

In one embodiment of the invention the therapeutic agent is an anti-cancer agent that bears one or more hydroxy groups. In another embodiment of the invention the therapeutic agent is a taxane. (see for example, Katsetos CD, Dráber P, Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside, *Curr Pharm Des.* 2012 Feb 28. [Epub ahead of print]; Singh S, Dash AK., Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges, *Crit Rev Ther Drug Carrier Syst.* 2009;26(4):333-72; and Natural Taxanes: Developments Since 1828. Wang, Yu-Fang; Shi, Qing-Wen; Dong, Mei; Kiyota, Hiromasa; Gu, Yu-Cheng; Cong, Bin *Chemical Reviews* (Washington, DC, United States) (2011), 111(12), 7652-7709). In another embodiment of the invention the therapeutic agent is paclitaxel or docetaxel.

Representative compounds of the invention were prepared from PTX as outlined in Figure 4.

Controlled Release Rates

The silicate prodrugs of the invention can be designed to have varying hydrophobicity and, independently, different rates of hydrolysis. Accordingly, different silicate prodrugs of a single drug (e.g. a taxane) can be designed to provide different rates of hydrolysis. By combining or administering two or more silicate prodrugs having different rates of hydrolysis it is possible to deliver a drug (e.g. a taxane) with a specifically designed release profile. For example, it is possible to administer compounds of the invention so that a controlled level of the drug (e.g. the taxane) is delivered over an extended period (e.g. 1-2 weeks) of time.

Accordingly, in one embodiment the invention provides a pharmaceutical composition comprising a) two or more compounds of the invention; and b) a pharmaceutically acceptable carrier. For example, the pharmaceutical composition can comprise a first compound of the

09531.308WO1 - 20110152

invention that comprises a taxane linked to one group of formula (I), and a second compound of the invention that comprises a taxane linked to two or more groups of formula (I). As another example, the pharmaceutical composition of the invention can comprise a first compound of the invention that comprises a taxane linked to one or more groups of formula (I) wherein R has a first value, and
5 a second compound of the invention that comprises a taxane linked to one or more groups of formula (I) wherein R has a second (different) value. It will be apparent that other pharmaceutical compositions having variable release profiles can be prepared by altering the number of groups of formula (I) and/or by altering the value for R in the compounds of the invention.

In another embodiment the invention provides a method to treat cancer in an animal
10 comprising administering to the animal two or more different compounds of the invention. In another embodiment the invention provides a method to treat cancer in an animal comprising administering to the animal a formulation of the invention that comprises two or more different compounds of the invention. In another embodiment the invention provides a method to treat cancer in an animal, comprising administering to the animal a nano-particle of the invention that
15 comprises two or more different compounds of the invention. In another embodiment the invention provides a method to treat cancer in an animal, comprising administering to the animal a first nano-particle of the invention that comprises one compound of the invention and a second nano-particle of the invention that comprises a different compound of the invention. For example, the compound of the invention in the first nano-particle and the compound of the invention in the
20 second nano-particle can be selected to provide a selected release profile of the drug (e.g. the taxane) over a selected period of time.

In another embodiment the invention provides a nano-particle comprising two or more different compounds of the invention. For example, the compounds of the invention can be selected to provide a selected release profile of the drug (e.g. the taxane) over a selected period of
25 time upon administration of the nano-particle.

Combination Therapy

The silicate prodrugs of the invention can be administered or used in combination with one or more additional therapeutic agents. The additional agent(s) can be administered separately or sequentially with the silicate prodrugs of the invention or they can be co-formulated with one or
30 more silicate prodrugs of the invention.

09531.308WO1 - 20110152

Suitable additional therapeutic agents that can be administered with or co-formulated with the silicate prodrugs of the invention include anti-cancer agents such as, for example, all-trans retinoic acid, Azacitidine, Azathioprine, Bleomycin, Bortezomib, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Etoposide, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Teniposide, Tioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine, Vinorelbine, and selective and non-selective tyrosine kinase inhibitors (e.g. lapatinib, dasatinib, vemurafenib, imatinib, gefitinib, erlotinib, and sunitinib, etc.). Other additional therapeutic agents that can be administered with or co-formulated with the silicate prodrugs of the invention include P-gp inhibitors (verapamil, cyclosporine, tariquidar, elacridar, etc) and CYP3A4 inhibitors (ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, bergamottin, cimetidine, voriconazole, fluoxetine/norfluoxetine, piperine, and silibinin, quercetin, etc).

Accordingly, in one embodiment the invention provides a pharmaceutical composition comprising a) a compound of the invention; b) one or more additional therapeutic agents; and c) a pharmaceutically acceptable carrier.

In another embodiment the invention provides a method to treat cancer in an animal comprising administering to the animal a compound of the invention, or a formulation of the invention, or a nano-particle of the invention in combination with one or more additional therapeutic agents.

In another embodiment the invention provides a nano-particle comprising a compound of the invention and one or more additional therapeutic agents. For example, the additional therapeutic agent(s) can be coated on a nano-particle comprising a compound of the invention or the additional therapeutic agent(s) can be incorporated into a nano-particle of the invention.

Targeted Therapy

The nano-particles of the invention can also incorporate one or more targeting groups that will facilitate delivery of the nano-particles to specific sites (e.g. tumors) in the body. For example, in one embodiment of the invention, the nano-particles of the invention can further comprise one or more targeting moieties that target a site on a tumor cell, for example, an EGFR that is overexpressed on many tumor cells.

09531.308WO1 - 20110152


Targeting moieties that can be incorporated into the nano-particles of the invention include: folic acid, biotin, a Cys-Arg-Glu-Lys-Ala (CREKA) peptide, mannose 6-phosphate, transferrin, a peptide targeting transferrin receptor, an epidermal growth factor receptor (EGFR) targeting peptide, an scFv or antibody, a CD133 targeting scFv or antibody, and peptides targeting the integrin
5 receptors.

In one embodiment of the invention, the targeting moiety can also possess its own therapeutic activity. Such targeting moieties can include: TRAIL, Cetuximab, Trastuzumab, Bevacizumab, Rituximab, Ibritumomab, Tositumomab, Alemtuzumab, and Epratuzumab.

The targeting moieties can be incorporated into the nano-particles in any suitable manner. For example, the targeting moieties can be associated with the nano-particles in a non-covalent
10 manner, or the targeting moieties can be covalently bonded to the nano-particles either directly or through a suitable linker. In one embodiment of the invention, the targeting moiety can be linked to a polymer component (e.g. a PEG-*b*-PLGA block co-polymer) of a nano-particle.

Scheme 1 illustrates the preparation of a PEG-*b*-PLGA block co-polymer that is linked to a
15 targeting moiety (an EGFRP). This PEG-*b*-PLGA block co-polymer can be incorporated into nano-particles of the invention. The non-functionalized copolymer **1**, can be converted to the maleimide (MAL) functional BCP **2** (for use in surface ligation), which can be attached to a targeting moiety (e.g. EGFRP) to provide the final BCP **3**, which carries a covalently bound EGFR targeting moiety.

Scheme 1. Synthesis of block copolymers 1-3 for use in Study 2b.




Scheme 2 illustrates the preparation of nano-particles of the invention using the polymer components described in Scheme 1 above. The surface reactive particles NP^{MAL}, which are

09531.308WO1 - 20110152

obtained from FNP of a prodrug and the BCPs **1** and **2**, can be used as key intermediates. *In situ* surface conjugation to the reactive MALs in NP^{MAL} by reaction with the cysteine-containing peptide **8** can be used to introduce an EGFRP targeting moiety. For this (as well as the synthesis of NP^{Cmab}) any remaining MAL groups can be capped by incubation with excess Cys. Note that the surface density of the targeting moiety present in the final nano-particle can be readily controlled by adjusting the ratio of either **2** or **3** vs. **1** as well as by the amount of **8** used in the derivatization of NP^{MAL}.

Scheme 2. Complementary strategies for incorporating Targeting Moieties selective for EGFR-positive tumor cells on the surface of prodrug-loaded NPs.



To prepare the **Cmab**-carrying particles—i.e., NP^{Cmab}—**Cmab** the 250 kDa antibody will first be thiolated by *N*-acylation of a few surface lysines with the disulfide **9**, followed by reduction to the free thiol **11** with the water-soluble phosphine **10**. Again, ligation through covalent bond formation between **11** and the MALs in the preformed NP^{MAL} will provide the prodrug-loaded NP^{Cmab}.

09531.308WO1 - 20110152

The Mal-substituted polymers and nano-particles (NP^{MAL}) described in Schemes 1 and 2 are useful intermediates for preparing the nano-particles of the invention and they represent embodiments of the invention.

Accordingly, in one embodiment the invention provides a nano-particle comprising a compound of the invention and one or more targeting moieties.

The *in vivo* activity of a compound or a formulation of the invention can be evaluated using the following model.

In Vivo Activity

A mouse xenograft tumor model, employing 6-8 week old ovariectomized female NCRNU-M mice (Taconic Farms), can be used. MCF-7 cells (5×10^6) can be used to induce tumors. Tumor growth will be facilitated by estrogen pellet implantation. A total of 324 animals are required for the studies [126 for study 1 (biodistribution study), 36 for study 2 (tumor growth inhibition study); two repeats].

Pellet implantation: Ovariectomized mice (Taconic Farms) can be used in order to avoid complications from ovarian response to elevated estrogen levels. Following 1 week acclimatization, animals can be implanted with estradiol pellets. To implant pellets, mice can be anesthetized with ketamine (80mg/kg) and xylazine (7 mg/kg) intraperitoneally using a 26 gauge needle. Following swabbing of the site with betadine (twice with circular motion from center to periphery), the estradiol pellet (*ca.* 2 mm in diameter) can be implanted under the skin with a sterile trocar, and the implantation site can be closed with tissue adhesive (Liquivet Rapid). Animals can be placed in cages on paper towels until recovery. During recovery the cages can be placed on a heating pad at low setting. Animals can be observed until mobility is recovered. No additional analgesics can be administered. All procedures can be performed under aseptic conditions.

Tumors can be induced by subcutaneous injection of 5×10^6 MCF-7 tumor cells suspended in 0.05 mL of Hank's phosphate buffered saline on the right flank. The subcutaneous injection can be administered using a 26-gauge needle. Tumor induction can be done two-three days following pellet implantation.

Tumor volume can be monitored on a regular basis using calipers. Length (L) and width (W) of

09531.308WO1 - 20110152

the tumor can be measured and its volume calculated using the equation: $(L \times 2W)/2$. Tumor volume and body weight can be measured every alternate day during the first month and twice a week in the 2nd and 3rd month after treatment administration.

5 Animals that develop 100-200 mm³ size tumors can be randomized into different treatment groups (see Specific Aim 3 methods). Tumor-bearing mice can be treated with single intravenous injection of different treatments in 200 µL of Hank's balanced salt solution using a 27-gauge needle. For biodistribution studies, animals can be treated and then euthanized (1 h, 6 h, 12 h, 24 h, 3 days, 1 week, and 2 weeks) for the collection of blood and other tissues. For tumor growth inhibition studies, animals can be observed for tumor growth and mortality over a 30-day period.

10 Animals can also be observed for body weight.

Animals that demonstrate weight loss of more than 20% of the initial weight and/or tumor weight equal to or more than 10% of the body weight can be removed from the study and euthanized.

The invention will now be illustrated by the following non-limiting Examples.

15

09531.308WO1 - 20110152

Examples

General

Paclitaxel was obtained from PhytoGen Life Sciences. Triethylamine and pyridine were purchased from Sigma Aldrich and purified by distillation over CaH_2 . Triethoxychlorosilane was purchased from Gelest. Silicon tetrachloride was purchased from Sigma Aldrich and transferred to a Schlenk flask under nitrogen and used to synthesize the tri-n-octyloxychlorosilane, tri-i-propoxychlorosilane, and di-t-butoxydichlorosilane [using n-octanol, i-propanol, and t-butanol (all purchased from Sigma Aldrich and dried over activated 3Å molecular sieves overnight), respectively]. Tetrahydrofuran was purchased from Fisher Scientific and dried by being passed through an activated alumina column. Ethanol (200 proof) was purchased from Decon Labs, Inc and further dried by storing over activated 3Å molecular sieves overnight. Ethyl acetate (ACS grade) was purchased from Macron Chemicals and used as received. Hexanes (ACS grade) were purchased from Fisher Scientific and used as received. The d_6 -acetone and d-chloroform was purchased from Cambridge Isotope Laboratories, Inc. and dried over activated 3Å molecular sieves overnight. D_2O was purchased from Cambridge Isotope Laboratories, Inc. and used as received.

Abraxane (Abraxis Biosciences, Los Angeles, CA, USA) was obtained from the Boynton health services pharmacy, University of Minnesota Twin Cities. Matrigel and D-Luciferin dipotassium salt were obtained from BD Pharmingen (San Diego, CA, USA). The PEG-b-PLGA block copolymer was synthesized as previously reported (see Qian H, et al., *Macromolecules*, **2011**, 44:7132–7140).

Medium Pressure Liquid Chromatography (MPLC) purifications were performed using columns dry packed with ca. 25-35 μm silica gel. The MPLC apparatus was pressurized with a Waters Chromatography Pump. Compound detection was performed by using a Gilson Model 111B UV Absorbance detector at 254 nm and a Waters Differential Refractometer in sequence. All thin layer chromatography (TLC) data was collected on glass-backed plates coated with F-254 indicator obtained from SiliCycle. Visualization was completed via UV-light and/or staining with phosphomolybdic acid (PMA). ^1H NMR spectra were taken on a Varian VI-500 (500 MHz ^1H). All ^1H characterization spectra were taken in CDCl_3 and chemical shifts (δ) are referenced to tetramethylsilane at $\delta = 0.00$. All ^{13}C NMR characterization spectra were taken in CDCl_3 on either a Bruker AV-500 (125 MHz ^{13}C) or a Varian VI-300 (75 MHz ^{13}C) and referenced to CHCl_3 at $\delta =$

09531.308WO1 - 20110152

77.23. The following abbreviations are used to describe the NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), sept (septet), m (multiplet), br (broad), and app (apparent). Coupling constants (J) are reported in Hz. Infrared spectra were recorded using a Midac Corporation Prospect 4000 FT-IR. All samples were collected in attenuated total reflectance mode as thin films on a germanium window. Melting point data were collected on a Köfler hot stage and are uncorrected. High resolution mass spectra were collected on a Bruker BioTOF II (ESI-TOF) instrument using poly(ethylene glycol) (PEG) or poly(propylene glycol) (PPG) as an internal standard.

Example 1. Preparation of 2',7-Di-*O*-(triethyl orthosilyl)paclitaxel (2a).

Paclitaxel (58.0 mg, 0.0679 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-dried culture tube fitted with a Teflon-lined cap and a stir bar. Pyridine (25 μ L, 0.309 mmol, 4.5 equiv) was added by Wiretrol[®]. Chlorotriethoxysilane (50 μ L, 0.255 mmol, 3.8 equiv) was added, and a white precipitate was immediately observed. The suspension was allowed to stir for 2 hours at room temperature and then diluted with hexanes:EtOAc (1:1). The slurry was filtered through a short plug of Celite[®] to remove the pyridinium salt, and the filtrate concentrated under reduced pressure. The residue was purified by MPLC (SiO₂, 2:1 hexanes:EtOAc) to yield **2a** as a white crystalline solid (68.0 mg, 0.058 mmol, 85%). If necessary, residual EtOAc was removed by storage under high vacuum for $\geq$ 24 h. ¹H NMR (500 MHz, CDCl₃): δ 8.12 (dd, J = 8.5, 1.5 Hz, 2H, C2O₂C-*o*-Ph), 7.78 (dd, J = 8.5, 1.5 Hz, 2H, C3'NHCO-*o*-Ph), 7.62 (tt, J = 7.5, 1.0 Hz, 1H, C2O₂C-*p*-Ph, 1H), 7.54-7.46 (m, 3H, C2O₂C-*m*-Ph and C3'NHCO-*p*-Ph), 7.44-7.36 (m, 6H, C3'-*o*-Ph, C3'-*m*-Ph and C3'NHCO-*m*-Ph), 7.29 (tt, J = 7.0, 1.5 Hz, 1H, C3'-*p*-Ph), 7.20 (d, J = 8.5 Hz, 1H, C3'NH), 6.58 (s, 1H, H10), 6.18 (br dd, J = 9, 9 Hz, 1H, H13), 5.72 (dd, J = 8.5, 3.0 Hz, 1H, H3'), 5.71 (d, J = 6.5 Hz, 1H, H2), 4.98 (d, J = 3.0 Hz, 1H, 2'H), 4.96 (dd, J = 10.0, 2.0 Hz, 1H, H5), 4.62 (dd, J = 10.5, 6.7 Hz, 1H, H7), 4.31 (d, J = 8.5 Hz, 1H, H20 α), 4.20 (d, J = 8.5 Hz, 1H, H20 β), 3.85 (d, J = 7.0 Hz, 1H, H3), 3.76 [q, J = 7.0 Hz, 6H, C7OSi(OCH₂CH₃)₃], 3.71 [q, J = 7.0 Hz, 6H, C2'OSi(OCH₂CH₃)₃], 2.66 (ddd, J = 14.5, 9.5, 6.5 Hz, 1H, H6 α), 2.45 (s, 3H, C4OAc), 2.33 (dd, J = 15.4, 9.4 Hz, 1H, H14 α), 2.15 (s, 3H, C10OAc), 2.08 (d, J = 1.5 Hz, 3H, C18H₃), 2.07 (dd, J = 15.1, 9.0 Hz, 1H, H14 β), 1.96 (ddd, J = 14.5, 10.8, 2.2 Hz, 1H, H6 β), 1.73 (s, 3H, C19H₃), 1.65 (br s, 1H, C1OH), 1.23 (s, 3H, C17H₃), 1.19 [t, J = 7.0 Hz, 9H, C7OSi(OCH₂CH₃)₃], 1.17 (s, 3H, C16H₃), and 1.15 [t, J = 7.0 Hz, 9H, C2'OSi(OCH₂CH₃)₃]. ¹³C NMR (75 MHz, CDCl₃): δ

09531.308WO1 - 20110152

202.6, 171.0, 169.8, 169.0, 167.3, 167.2, 141.0, 138.2, 134.3, 133.9, 133.3, 132.0, 130.4, 129.4, 128.9, 128.8, 128.7, 128.1, 127.3, 126.8, 84.5, 81.2, 78.9, 76.7, 75.9, 75.02, 74.99, 72.1, 71.6, 59.7, 59.5, 58.3, 55.5, 46.9, 43.4, 36.5, 35.5, 26.7, 23.0, 21.4, 21.0, 18.0 (x2), 14.2, and 10.4. **HRMS** (ESI) Calcd for $C_{59}H_{79}NNaO_{20}Si_2$ $[M + Na]^+$ 1200.4626, found 1200.4631. **IR** (thin film) 3500 (br), 2976, 2928, 2896, 1744, 1725, 1644, 1603, 1580, 1541, 1486, 1451, 1370, 1314, 1268, 1238, 1169, 1098, 1080, 1027, 969, 891, 842, 795, and 708 cm^{-1} . **mp** = 121-123 °C. **TLC** R_f (2:1 Hexanes:EtOAc) = 0.4.

Example 2. Preparation of 2'-O-(triethyl orthosilyl)paclitaxel (1a).

Paclitaxel (55.3 mg, 0.0648 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. Triethylamine (20 μ L, 0.130 mmol, 2.0 equiv) was added by Wiretrol[®]. Chlorotriethoxysilane (25 μ L, 0.0127 mmol, 2.0 equiv) was then added, and a white precipitate was immediately observed. The culture tube was sealed and the suspension was allowed to stir for 1 hour at room temperature. The reaction slurry was diluted with a mixture of hexanes:EtOAc (1:1) and filtered through a short plug of Celite[®] to remove the triethylammonium salt. The filtrate was concentrated under reduced pressure, and the residue redissolved in a mixture of hexanes:EtOAc (1:1). Chromatography (SiO₂, 1:1 hexanes:EtOAc) via MPLC yielded the title compound as a white, crystalline solid (59.6 mg, 0.0587 mmol, 90.6%). If necessary, residual EtOAc was removed by storage under high vacuum for ≥ 24 h. **¹H NMR** (500 MHz, CDCl₃): δ 8.12 (dd, J = 8.5, 1.4 Hz, 2H, C2O₂C-*o*-Ph), 7.78 (dd, J = 8.5, 1.3 Hz, 2H, C3'NHCO-*o*-Ph), 7.62 (tt, J = 7.5, 1.2 Hz, 1H, C2O₂C-*p*-Ph, 1H), 7.56-7.46 (m, 3H, C2O₂C-*m*-Ph and C3'NHCO-*p*-Ph), 7.43-7.36 (m, 6H, C3'-*o*-Ph, C3'-*m*-Ph and C3'NHCO-*m*-Ph), 7.29 (tt, J = 6.5, 2.2 Hz, 1H, C3'-*p*-Ph), 7.19 (d, J = 8.6 Hz, 1H, C3'NH), 6.28 (s, 1H, H10), 6.24 (br dd, J = 9, 9 Hz, 1H, H13), 5.72 (dd, J = 8.5, 3.2 Hz, 1H, H3'), 5.68 (d, J = 7.1 Hz, 1H, H2), 4.97 (dd, J = 9.4, 2.0 Hz, 1H, H5), 4.96 (d, J = 3.3 Hz, 1H, H2'), 4.43 (ddd, J = 10.9, 6.4, 4.5 Hz, 1H, H7), 4.32 (d, J = 8.5 Hz, 1H, H20 α), 4.20 (d, J = 8.5 Hz, 1H, H20 β), 3.80 (d, J = 7.2 Hz, 1H, H3), 3.71 [q, J = 7.0 Hz, 6H, C2'OSi(OCH₂CH₃)₃], 2.56 (ddd, J = 14.7, 9.6, 6.5 Hz, 1H, H6 α), 2.45 (s, 3H, C4OAc), 2.44 (br s, 1H, C7OH), 2.32 (dd, J = 15.4, 9.4, Hz, 1H, H14 α), 2.24 (s, 3H, C10OAc), 2.08 (dd, J = 15.2, 8.8 Hz, 1H, H14 β), 1.90 (d, J = 1.2 Hz, 3H, C18H₃), 1.89 (ddd, J = 14.5, 11.0, 2.4 Hz, 1H, H6 β), 1.68 (s, 3H, C19H₃), 1.64 (br s, 1H, C1OH), 1.24 (s, 3H, C17H₃),

09531.308WO1 - 20110152

1.15 [t, $J = 7.0$ Hz, 9H, C2'OSi(OCH₂CH₃)₃], and 1.13 (s, 3H, C16H₃). ¹³C NMR (75 MHz, CDCl₃): δ 204.0, 171.6, 171.0, 170.1, 167.3, 167.2, 143.0, 138.2, 134.2, 133.9, 132.9, 132.0, 130.4, 129.3, 128.9 (x2), 128.8, 128.2, 127.3, 126.8, 84.6, 81.2, 79.3, 76.7, 75.8, 75.3, 75.1, 72.3, 71.5, 59.7, 58.7, 55.6, 45.7, 43.4, 35.7, 35.6, 27.0, 23.0, 22.4, 21.1, 18.2, 14.9, and 9.8. HRMS (ESI) Calcd for C₅₃H₆₅NNaO₁₇Si [M + Na]⁺ 1038.3914, found 1038.3942. IR (thin film) 3500 (br), 2977, 2898, 1744, 1730, 1636, 1580, 1540, 1487, 1452, 1371, 1314, 1268, 1240, 1170, 1145, 1078, 1025, 978, 908, 854, 797, and 710 cm⁻¹. mp = 131-134 °C. TLC R_f (1:1 Hexanes:EtOAc) = 0.45.

Example 3. Preparation of 2-O-(tri-*n*-octyl orthosilyl)paclitaxel (1b).

Paclitaxel (76.0 mg, 0.0890 mmol, 1.0 equiv) was dissolved in dry THF (1.5 mL) in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. Triethylamine (60 μ L, 0.430 mmol, 4.8 equiv) was added by Wiretrol[®]. A 1.67:1 mixture of tri-*n*-octyloxychlorosilane:tetra-*n*-octyloxysilane (0.200 mg, 0.257 mmol, 2.9 equiv of tri-*n*-octyloxychlorosilane) was added and a white precipitate was immediately observed. The culture tube was sealed and the suspension was allowed to stir for 22 h at room temperature. The reaction slurry was diluted with a mixture of hexanes:EtOAc (1:1), the slurry filtered through a short plug of Celite[®] to remove the triethylammonium salt, the filtrate concentrated under reduced pressure, and the residue redissolved in a mixture of hexanes:EtOAc (2:1). Chromatography (SiO₂, 2:1 hexanes:EtOAc) via MPLC yielded the title compound as a white, crystalline solid (91.5 mg, 0.0721 mmol, 81.0%). If necessary, residual EtOAc was removed by storage under high vacuum for ≥ 24 h. ¹H NMR (500 MHz, CDCl₃): δ 8.13 (dd, $J = 8.5, 1.5$ Hz, 2H, C2O₂C-*o*-Ph), 7.77 (dd, $J = 8.5, 1.4$ Hz, 2H, C3'NHCO-*o*-Ph), 7.62 (tt, $J = 7.4, 1.3$ Hz, 1H, C2O₂C-*p*-Ph), 7.55-7.46 (m, 3H, C2O₂C-*m*-Ph and C3'NHCO-*p*-Ph), 7.43-7.35 (m, 6H, C3'-*o*-Ph, C3'-*m*-Ph and C3'NHCO-*m*-Ph), 7.28 (tt, $J = 6.9, 1.7$ Hz, 1H, C3'-*p*-Ph), 7.19 (d, $J = 8.6$ Hz, 1H, C3'NH), 6.28 (s, 1H, H10), 6.25 (br dd, $J = 9, 9$ Hz, 1H, H13), 5.72 (dd, $J = 8.6, 3.2$ Hz, 1H, H3'), 5.68 (d, $J = 7.1$ Hz, 1H, H2), 4.97 (dd, $J = 9.8, 2.1$ Hz, 1H, H5), 4.96 (d, $J = 3.2$ Hz, 1H, H2'), 4.44 (ddd, $J = 10.9, 6.7, 4.2$ Hz, 1H, H7), 4.31 (d, $J = 8.4$ Hz, 1H, H20 α), 4.20 (d, $J = 8.3$ Hz, 1H, H20 β), 3.80 (d, $J = 7.1$ Hz, 1H, H3), 3.61 {t, $J = 6.8$ Hz, 6H, C2'OSi[OCH₂(CH₂)₆CH₃]₃}, 2.56 (ddd, $J = 14.8, 9.6, 6.6$ Hz, 1H, H6 α), 2.47 (d, $J = 4.1$ Hz, 1H, C7OH), 2.44 (s, 3H, C4OAc), 2.32 (dd, $J = 15.4, 9.4$ Hz, 1H, H14 α), 2.24 (s, 3H, C10OAc), 2.07 (dd, $J = 15.4, 8.8$ Hz, 1H, H14 β), 1.89 (d, $J = 1.4$ Hz, 3H, C18H₃), 1.89 (m, 1H, H6 β), 1.68 (s, 3H, C19H₃), 1.65 (br s, 1H, C1OH), 1.48 [tt, $J = 6.9, 6.9$ Hz,

09531.308WO1 - 20110152

6H, C2'OSi(OCH₂CH₂(CH₂)₅CH₃)₃], 1.32-1.22 {m, 33H, C2'OSi[OCH₂CH₂(CH₂)₅CH₃]₃ and C17H₃}, 1.13 (s, 3H, C16H₃), and 0.88 {t, *J* = 6.9 Hz, 9H, C2'OSi[OCH₂CH₂(CH₂)₅CH₃]₃}. ¹³C NMR (75 MHz, CDCl₃): δ 204.0, 171.5, 170.9, 170.1, 167.2, 167.2, 143.0, 138.3, 134.3, 133.9, 132.9, 132.0, 130.4, 129.3, 128.9 (x2), 128.8, 128.1, 127.3, 126.8, 84.7, 81.2, 79.3, 76.6, 75.8, 75.3, 74.9, 72.4, 71.4, 64.1, 58.7, 55.5, 45.7, 43.4, 35.8, 35.7, 32.4, 32.0, 29.54, 29.52, 27.0, 25.8, 23.0, 22.9, 22.4, 21.1, 14.9, 14.3, and 9.8. HRMS (ESI) Calcd for C₇₁H₁₀₁NNaO₁₇Si [M + Na]⁺ 1290.6731; found 1290.6749. IR (thin film) 2926, 2855, 1730, 1665, 1643, 1602, 1581, 1518, 1484, 1453, 1371, 1312, 1271, 1240, 1174, 1094, 1025, 985, 926, 907, 851, 801, 777, and 711 cm⁻¹. mp = 60-63 °C. TLC R_f (3:1 Hexanes:EtOAc) = 0.15.

Example 4. Preparation of 2'-O-(tri-*i*-propyl orthosilyl)paclitaxel (1c).

Paclitaxel (38.8 mg, 0.0454 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. Triethylamine (25 μL, 0.179 mmol, 3.9 equiv) was added by Wiretrol[®]. A 2.9:1 mixture of tri-*i*-propoxychlorosilane:tetra-*i*-propoxysilane (0.155 mg, 0.132 mmol, 2.9 equiv of tri-*i*-propoxychlorosilane) was added. The culture tube was sealed and a white precipitate was observed within minutes. The suspension was stirred at room temperature for 48 hours and the cloudy, heterogeneous reaction mixture was noted to be slightly yellowed. The suspension was diluted with a mixture of hexanes:EtOAc (1:1), the slurry filtered through a short plug of Celite[®] to remove the triethylammonium salt, the filtrate concentrated under reduced pressure, and the residue redissolved in a mixture of hexanes:EtOAc (1:1). Chromatography (SiO₂, 1:1 hexanes:ethyl acetate) via MPLC yielded the title compound as a white, crystalline solid (31.1 mg, 0.0294 mmol, 64.7%). If necessary, residual EtOAc was removed by storage under high vacuum for ≥ 24h. ¹H NMR (500 MHz, CDCl₃): δ 8.11 (dd, *J* = 8.5, 1.4 Hz, 2H, C2O₂C-*o*-Ph), 7.79 (dd, *J* = 8.4, 1.3 Hz, 2H, C3'NHCO-*o*-Ph), 7.62 (tt, *J* = 7.6, 1.3 Hz, 1H, C2O₂C-*p*-Ph, 1H), 7.55-7.47 (m, 3H, C2O₂C-*m*-Ph and C3'NHCO-*p*-Ph), 7.44-7.35 (m, 6H, C3'-*o*-Ph, C3'-*m*-Ph and C3'NHCO-*m*-Ph), 7.27 (tt, *J* = 7.0, 1.7 Hz, 1H, C3'-*p*-Ph), 7.17 (d, *J* = 8.5 Hz, 1H, C3'NH), 6.28 (s, 1H, H10), 6.19 (br dd, *J* = 9, 9 Hz, 1H, H13), 5.69 (dd, *J* = 8.5, 3.6 Hz, 1H, H3'), 5.68 (d, *J* = 6.7 Hz, 1H, H2), 4.98 (d, *J* = 3.6 Hz, 1H, H2'), 4.96 (dd, *J* = 9.7, 2.4 Hz, 1H, H5), 4.44 (ddd, *J* = 10.9, 6.6, 4.1 Hz, 1H, H7), 4.31 (d, *J* = 8.4 Hz, 1H, H20α), 4.20 (d, *J* = 8.4 Hz, 1H, H20β), 4.13 {sept, *J* = 6.1 Hz, 3H, C2'OSi[OCH(CH₃)₂]₃}, 3.80 (d, *J* = 7.1 Hz, 1H, H3), 2.56

09531.308WO1 - 20110152

(ddd, $J = 14.8, 9.8, 6.6$ Hz, 1H, H6 α), 2.47 (d, $J = 4.1$ Hz, 1H, C7OH), 2.42 (s, 3H, C4OAc), 2.29 (dd, $J = 15.4, 9.4$ Hz, 1H, H14 α), 2.24 (s, 3H, C10OAc), 2.06 (dd, $J = 15.4, 8.9$ Hz, 1H, H14 β), 1.91 (d, $J = 1.4$ Hz, 3H, C18H₃), 1.88 (ddd, $J = 14.3, 11.0, 2.4$ Hz, 1H, H6 β), 1.76 (br s, 1H, C1OH), 1.68 (s, 3H, C19H₃), 1.23 (s, 3H, C17H₃), 1.15 {d, $J = 6.1$ Hz, 9H, C2'OSi[OCH(CH₃)_a(CH₃)_b]₃}, 1.12 {d, $J = 6.1$ Hz, 9H, C2'OSi[OCH(CH₃)_a(CH₃)_b]₃}, and 1.12 (s, 3H, C16H₃). ¹³C NMR (125 MHz, CDCl₃): δ 204.1, 171.5, 171.1, 170.1, 167.3, 167.2, 143.1, 138.3, 134.4, 133.9, 132.9, 131.9, 130.4, 129.4, 128.9 (x2), 128.8, 128.1, 127.3, 127.0, 84.7, 81.2, 79.3, 76.7, 75.9, 75.3, 74.9, 72.3, 71.5, 66.7, 58.7, 55.8, 45.7, 43.4, 35.8, 35.7, 27.0, 25.44, 25.42, 23.0, 22.4, 21.1, 15.2, and 9.8. HRMS (ESI) Calcd for C₅₆H₇₁NNaO₁₇Si [M + Na]⁺ 1080.4383; found 1080.4380. IR (thin film) 3500 (br), 2974, 2934, 1729, 1666, 1603, 1583, 1515, 1485, 1452, 1371, 1313, 1269, 1241, 1174, 1114, 1052, 985, 897, 850, 800, 773, and 712 cm⁻¹. mp = 126-129 °C. TLC R_f (1:1 Hexanes:EtOAc) = 0.45.

Example 5. Preparation of 2'-O-(di-*t*-butyl ethyl orthosilyl)paclitaxel (1d).

Paclitaxel (49.3 mg, 0.0577 mmol, 1.0 equiv) was dissolved in dry THF (1.0 mL) in an oven-dried culture tube with a Teflon-lined cap and magnetic stir bar. Pyridine (0.12 mL, 1.48 mmol, 26 equiv) was added by syringe. A distilled sample of di-*t*-butoxydichlorosilane (0.349 mg, 1.42 mmol, 25 equiv) was added by Wiretrol[®]. The culture tube was sealed and the solution was allowed to stir at room temperature. A small amount of a white precipitate was observed after ca. 30 minutes, and the reaction mixture was noted to be cloudy and heterogeneous after stirring for 6 hours. To the suspension, pyridine was again added (0.47 mL, 5.81 mmol, 100 equiv). Immediately afterward, anhydrous ethanol (dried overnight over 3Å molecular sieves, 0.68 mL, 11.7 mmol, 200 equiv) was added. The mixture was allowed to stir for one additional hour at room temperature. Analysis of the crude mixture was completed by removing a 0.1 mL aliquot of the reaction solution, removing the volatile components under reduced pressure, and analyzing the crude ¹H NMR spectrum. The results indicated that the reaction was complete. The remainder of the reaction suspension was diluted with a mixture of hexanes:EtOAc (1:1), the slurry filtered through a short plug of Celite[®] to remove the pyridinium salt, the filtrate concentrated under reduced pressure, and the residue redissolved in a mixture of hexanes:EtOAc (2:1). Chromatography (SiO₂, 2:1 hexanes:EtOAc) via MPLC yielded the title compound as a white, crystalline solid (52.0 mg,

09531.308WO1 - 20110152

0.0485 mmol, 84.1%). If necessary, residual EtOAc was removed by storage under high vacuum for ≥ 24 h. **¹H NMR** (500 MHz, CDCl₃): δ 8.11 (dd, $J = 8.5, 1.4$ Hz, 2H, C2O₂C-*o*-Ph), 7.79 (dd, $J = 8.4, 1.4$ Hz, 2H, C3'NHCO-*o*-Ph), 7.62 (tt, $J = 7.4, 1.3$ Hz, 1H, C2O₂C-*p*-Ph, 1H), 7.56-7.46 (m, 3H, C2O₂C-*m*-Ph and C3'NHCO-*p*-Ph), 7.45-7.33 (m, 6H, C3'-*o*-Ph, C3'-*m*-Ph and C3'NHCO-*m*-Ph), 7.30-7.22 (m, 1H, C3'-*p*-Ph), 7.15 (d, $J = 8.4$ Hz, 1H, C3'NH), 6.28 (s, 1H, H10), 6.18 (br dd, $J = 9, 9$ Hz, 1H, H13), 5.68 (d, $J = 7.2$ Hz, 1H, H2), 5.66 (dd, $J = 8.3, 3.6$ Hz, 1H, H3'), 5.01 (d, $J = 3.6$ Hz, 1H, H2'), 4.97 (dd, $J = 9.7, 2.3$ Hz, 1H, H5), 4.44 (ddd, $J = 10.8, 6.6, 4.1$ Hz, 1H, H7), 4.31 (d, $J = 8.4$ Hz, 1H, H20 α), 4.19 (d, $J = 8.4$ Hz, 1H, H20 β), 3.79 (d, $J = 7.0$ Hz, 1H, H3), 3.64 (q, $J = 7.0$ Hz, 2H, C2'OSiOCH₂CH₃), 2.56 (ddd, $J = 14.8, 9.7, 6.6$ Hz, 1H, H6 α), 2.45 (d, $J = 4.1$ Hz, 1H, C7OH), 2.41 (s, 3H, C4OAc), 2.28 (dd, $J = 15.4, 9.4$ Hz, 1H, H14 α), 2.24 (s, 3H, C10OAc), 2.05 (dd, $J = 15.3, 9.0$ Hz, 1H, H14 β), 1.90 (d, $J = 1.4$ Hz, 3H, C18H₃), 1.88 (ddd, $J = 14.4, 11.1, 2.5$ Hz, 1H, H6 β), 1.68 (s, 4H, C1OH and C19H₃), 1.26 (s, 9H, C2'OSiOC(CH₃)₂), 1.25 (s, 9H, C2'OSiOC(CH₃)₂), 1.23 (s, 3H, C17H₃), and 1.13 (overlapping t, $J = 7.0$ Hz, 3H, C2'OSiCH₂CH₃ and s, 3H, C16H₃). **¹³C NMR** (125 MHz, CDCl₃): δ 204.1, 171.5, 171.0, 170.0, 167.3, 167.2, 143.1, 138.4, 134.4, 133.9, 132.8, 131.9, 130.4, 129.4, 128.90, 128.89, 128.8, 128.1, 127.3, 127.0, 84.7, 81.2, 79.3, 76.6, 75.9, 75.3, 74.9, 73.99, 73.98, 72.3, 71.4, 59.3, 58.7, 55.8, 45.7, 43.4, 35.8, 35.7, 31.41, 31.38, 27.0, 22.9, 22.3, 21.1, 18.2, 15.1, and 9.8. **IR** (thin film) 3500 (br), 2976, 2936, 1726, 1665, 1603, 1582, 1514, 1485, 1452, 1389, 1368, 1312, 1270, 1242, 1179, 1128, 1069, 1025, 981, 909, 853, 821, 800, 775, 733, and 711 cm⁻¹. **HRMS** (ESI) Calcd for C₅₇H₇₃NNaO₁₇Si [M + Na]⁺ 1094.4540; found 1094.4579. **mp** = 130-134 °C. **TLC** R_f (2:1 Hexanes:EtOAc) = 0.2.

Example 6. Preparation of 2',7-Di-O-(tri-*n*-octyl orthosilyl)paclitaxel (2b).

Paclitaxel (57.8 mg, 0.0677 mmol, 1.0 equiv) was dissolved in dry THF (1.5 mL) in an oven-dried culture tube fitted with a Teflon-lined cap and magnetic stir bar. Pyridine (25 μ L, 0.309 mmol, 4.6 equiv) was added by Wiretrol[®]. A 1.67:1 mixture of tri-*n*-octyloxychlorosilane:tetra-*n*-octyloxysilane (0.155 mg, 0.199 mmol, 2.9 equiv of tri-*n*-octyloxychlorosilane) was added, and formation of a white precipitate was immediately observed. The culture tube was sealed and the suspension was allowed to stir for 5 h at room temperature. The reaction mixture was diluted with a mixture of hexanes:EtOAc (1:1), and the slurry filtered through a short plug of Celite[®] to remove

09531.308WO1 - 20110152

the pyridinium salt. The filtrate was concentrated under reduced pressure, and the residue purified by MPLC (SiO₂, 9:1 hexanes:EtOAc) to yield **2b** as a viscous oil (88.1 mg, 0.0523 mmol, 77.3%). Additional elution in hexanes:EtOAc (2:1) yielded **1b** (1.7 mg, 0.0013 mmol, 2.0 %). If necessary, residual EtOAc was removed from **2b** by storage under high vacuum for ≥ 24 h. ¹H NMR (500

5 MHz, CDCl₃): δ 8.13 (dd, $J = 8.6, 1.4$ Hz, 2H, C2O₂C-*o*-Ph), 7.78 (dd, $J = 8.6, 1.5$ Hz, 2H, C3'NHCO-*o*-Ph), 7.60 (tt, $J = 7.4, 1.2$ Hz, 1H, C2O₂C-*p*-Ph, 1H), 7.54-7.46 (m, 3H, C2O₂C-*m*-Ph and C3'NHCO-*p*-Ph), 7.44-7.35 (m, 6H, C3'-*o*-Ph, C3'-*m*-Ph and C3'NHCO-*m*-Ph), 7.28 (tt, $J = 7.2, 1.3$ Hz, 1H, C3'-*p*-Ph), 7.22 (d, $J = 8.7$ Hz, 1H, C3'NH), 6.55 (s, 1H, H10), 6.23 (br dd, $J = 10, 9$ Hz, 1H, H13), 5.74 (dd, $J = 8.6, 3.0$ Hz, 1H, H3'), 5.70 (d, $J = 7.1$ Hz, 1H, H2), 4.99 (d, $J = 3.0$ Hz, 1H, 2'H), 4.94 (dd, $J = 9.7, 1.9$ Hz, 1H, H5), 4.61 (dd, $J = 10.6, 6.8$ Hz, 1H, H7), 4.31 (d, $J = 8.4$ Hz, 1H, H20 α), 4.20 (d, $J = 8.4$ Hz, 1H, H20 β), 3.86 (d, $J = 7.0$ Hz, 1H, H3), 3.67 {t, $J = 6.7$ Hz, 6H, C7OSi[OCH₂(CH₂)₆CH₃]₃}, 3.61 {t, $J = 6.7$ Hz, 6H, C2'OSi[OCH₂(CH₂)₆CH₃]₃}, 2.65 (ddd, $J = 14.7, 9.7, 6.8$ Hz, 1H, H6 α), 2.45 (s, 3H, C4OAc), 2.33 (dd, $J = 15.3, 9.4$ Hz, 1H, H14 α) 2.13 (s, 3H, C10OAc),), 2.06 (d, $J = 1.2$ Hz, 3H, C18H₃), 2.09-2.02 (m, 1H, H14 β), 1.96 (ddd, $J = 14.5, 10.8, 2.2$ Hz, 1H, H6 β), 1.73 (s, 3H, C19H₃), 1.66 (br s, 1H, C1OH), 1.56-1.44 {m, 12H, C2'OSi[OCH₂CH₂(CH₂)₅CH₃]₃ and C7OSi[OCH₂CH₂(CH₂)₅CH₃]₃}, 1.34-1.21 {m, 63H, C17H₃, C2'OSi[OCH₂CH₂(CH₂)₅CH₃]₃, and C7OSi[OCH₂CH₂(CH₂)₅CH₃]₃}, 1.17 (s, 3H, C16H₃), and 0.88 {overlapping t's, $J = 6.8$ Hz, 18H, C2'OSi[OCH₂CH₂(CH₂)₅CH₃]₃ and C7OSi[OCH₂CH₂(CH₂)₅CH₃]₃}. ¹³C NMR (75 MHz, CDCl₃): δ 202.4, 170.9, 169.8, 168.7, 167.3, 167.2, 140.9, 138.3, 134.3, 133.8, 133.3, 131.9, 130.4, 129.4, 128.91, 128.89, 128.8, 128.1, 127.3, 126.8, 84.6, 81.2, 79.0, 76.8, 75.8, 75.1, 74.9, 72.0, 71.5, 64.1, 63.9, 58.3, 55.5, 46.8, 43.5, 36.6, 35.6, 32.5, 32.4, 32.1, 32.0, 29.6, 29.63, 29.60, 29.57, 26.7, 25.92, 25.89, 23.0, 22.91, 22.90, 21.6, 21.1, 14.3 (x2), 14.1, and 10.4. HRMS (ESI) Calcd for C₉₅H₁₅₁NNaO₂₀Si₂ [M + Na]⁺ 1705.0260; found 1705.0228. IR (thin film) 3500 (br), 2927, 2856, 1728, 1741, 1721, 1634, 1580, 1545, 1456, 1371, 1315, 1270, 1239, 1174, 1095, 1028, 989, 968, 924, 893, 843, 779, and 709 cm⁻¹. TLC R_f (3:1 Hexanes:EtOAc) = 0.55.

Example 7. Preparation of 7-O-(triethyl orthosilyl)paclitaxel (**3a**).

Bis-silicate ester **2a** (99.5 mg, 0.0845 mmol, 1.0 equiv) was dissolved in *d*₆-acetone (1.8 mL, dried over 3Å molecular sieves) in an NMR tube. A 9:1 mixture of D₂O:TFA was added (200

09531.308WO1 - 20110152

5 μL) and the reaction progress was monitored by ^1H NMR spectroscopy. After eight minutes at 21.4 °C, the mixture was transferred into saturated aqueous NaHCO_3 (2 mL). This mixture was extracted with CH_2Cl_2 (3 x 5 mL). The combined organic extracts were dried over MgSO_4 and concentrated under reduced pressure. The residue was purified by MPLC (SiO_2 , 2:1 hexanes:EtOAc) to provide

10 recovered starting material **2a** (27.3 mg, 0.0232 mmol, 27.4%). Additional elution in 1:1 hexanes:EtOAc gave the title compound as a white, crystalline solid [56.9 mg, 0.0560 mmol, 66.3% (91.4% brsm)]. If necessary, residual EtOAc was removed by storage under high vacuum for ≥ 24 h. **^1H NMR** (500 MHz, CDCl_3): δ 8.12 (dd, $J = 8.5, 1.3$ Hz, 2H, $\text{C}_2\text{O}_2\text{C}-o\text{-Ph}$), 7.75 (dd, $J = 8.5, 1.4$ Hz, 2H, $\text{C}_3'\text{NHCO}-o\text{-Ph}$), 7.61 (tt, $J = 7.5, 1.2$ Hz, 1H, $\text{C}_2\text{O}_2\text{C}-p\text{-Ph}$, 1H), 7.53-7.46 (m, 5H,

15 $\text{C}_2\text{O}_2\text{C}-m\text{-Ph}$, $\text{C}_3'\text{NHCO}-p\text{-Ph}$, and $\text{C}_3'-o\text{-Ph}$), 7.43-7.37 (m, 4H, $\text{C}_3'-m\text{-Ph}$ and $\text{C}_3'\text{NHCO}-m\text{-Ph}$), 7.34 (tt, $J = 7.3, 1.2$ Hz, 1H, $\text{C}_3'-p\text{-Ph}$), 7.09 (d, $J = 9.0$ Hz, 1H, $\text{C}_3'\text{NH}$), 6.56 (s, 1H, H10), 6.18 (br dd, $J = 9, 9$ Hz, 1H, H13), 5.80 (dd, $J = 6.9, 2.5$ Hz, 1H, H3'), 5.69 (d, $J = 6.9$ Hz, 1H, H2), 4.93 (dd, $J = 9.6, 1.7$ Hz, 1H, H5), 4.78 (dd, $J = 4.9, 2.7$ Hz, 1H, 2'H), 4.57 (dd, $J = 10.5, 6.9$ Hz, 1H, H7), 4.30 (d, $J = 8.4$ Hz, 1H, H20 α), 4.19 (dd, $J = 8.3, 0.9$ Hz, 1H, H20 β), 3.83 (d, $J = 6.9$ Hz,

20 1H, H3), 3.76 [q, $J = 7.0$ Hz, 6H, $\text{C}_7\text{OSi}(\text{OCH}_2\text{CH}_3)_3$], 3.69 (br s, 1H, $\text{C}_2'\text{OH}$), 2.65 (ddd, $J = 14.7, 9.7, 6.9$ Hz, 1H, H6 α), 2.37 (s, 3H, C_4OAc), 2.35-2.25 (m, 2H, H14 α and H14 β), 2.15 (s, 3H, C_{10}OAc), 1.95 (ddd, $J = 14.6, 10.7, 2.1$ Hz, 1H, H6 β), 1.93 (d, $J = 1.3$ Hz, 3H, C_{18}H_3), 1.76 (br s, 1H, C_{10}OH), 1.73 (s, 3H, C_{19}H_3), 1.23 (s, 3H, C_{17}H_3), 1.19 [t, $J = 7.0$ Hz, 9H, $\text{C}_7\text{OSi}(\text{OCH}_2\text{CH}_3)_3$], and 1.16 (s, 3H, C_{16}H_3). **^{13}C NMR** (125 MHz, CDCl_3): δ 202.4, 172.6,

25 170.4, 169.0, 167.2, 167.1, 140.1, 138.2, 133.9, 133.8, 132.1, 130.3, 129.4, 129.1, 128.89, 128.87, 128.5, 127.3, 127.24, 127.23, 84.4, 81.5, 78.8, 76.8, 76.1, 74.8, 73.4, 72.5, 72.1, 59.5, 58.6, 55.0, 47.0, 43.4, 36.7, 35.6, 26.8, 22.9, 21.1, 21.0, 18.2, 14.5, and 10.3. **HRMS** (ESI) Calcd for $\text{C}_{53}\text{H}_{65}\text{NNaO}_{17}\text{Si}$ [$\text{M} + \text{Na}$] $^+$ 1038.3914, found 1038.3914. **IR** (thin film) 3500 (br), 2975, 2898, 1724, 1653, 1602, 1580, 1515, 1485, 1451, 1394, 1370, 1314, 1266, 1240, 1172, 1079, 1025, 969,

913, 888, 839, 797, and 712 cm^{-1} . **mp** = 141-146 °C. **TLC** R_f (1:1 Hexanes:EtOAc) = 0.5.

Example 8. Preparation of 7-O-(tri-n-octyl orthosilyl)paclitaxel (3b).

Bis-silicate ester **2b** (88.1 mg, 0.0523 mmol, 1.0 equiv) was dissolved in d_6 -acetone (1.8 mL, dried over 3Å molecular sieves) in an NMR tube. A 9:1 mixture of D_2O :TFA was added (200

30 μL) and the solution became white and cloudy. Upon vigorous mixing for 30 seconds, the mixture

09531.308WO1 - 20110152

became homogeneous and transparent. The hydrolysis progress was monitored by ^1H NMR spectroscopy. After 30 minutes at room temperature, the solution was transferred into saturated aqueous NaHCO_3 (2 mL). This mixture was extracted with CH_2Cl_2 (3 x 5 mL). The combined organic layers were dried over MgSO_4 and concentrated under reduced pressure. The residue was


5 purified by MPLC (SiO_2 , 3:1 hexanes:EtOAc) to provide recovered **2b** (12.9 mg, 0.0076 mmol, 27.4%). Additional elution in 2:1 hexanes:EtOAc gave the title compound as a crystalline solid [37.3 mg, 0.0294 mmol, 56.2% (65.7% brsm)]. If necessary, residual EtOAc was removed by storage under high vacuum for ≥ 24 h. ^1H NMR (500 MHz, CDCl_3): δ 8.12 (dd, $J = 8.5, 1.3$ Hz, 2H, $\text{C}_2\text{O}_2\text{C}-o\text{-Ph}$), 7.75 (dd, $J = 8.5, 1.4$ Hz, 2H, $\text{C}_3'\text{NHCO}-o\text{-Ph}$), 7.61 (tt, $J = 7.4, 1.3$ Hz, 1H, $\text{C}_2\text{O}_2\text{C}-p\text{-Ph}$, 1H), 7.53-7.47 (m, 5H, $\text{C}_2\text{O}_2\text{C}-m\text{-Ph}$, $\text{C}_3'\text{NHCO}-p\text{-Ph}$, and $\text{C}_3'-o\text{-Ph}$), 7.43-7.38 (m, 4H, $\text{C}_3'-m\text{-Ph}$ and $\text{C}_3'\text{NHCO}-m\text{-Ph}$), 7.34 (tt, $J = 7.2, 1.3$ Hz, 1H, $\text{C}_3'-p\text{-Ph}$), 7.06 (d, $J = 9.0$ Hz, 1H, $\text{C}_3'\text{NH}$), 6.53 (s, 1H, H10), 6.17 (br dd, $J = 9, 9$ Hz, 1H, H13), 5.81 (dd, $J = 6.8, 2.4$ Hz, 1H, H3'), 5.68 (d, $J = 6.9$ Hz, 1H, H2), 4.92 (dd, $J = 9.6, 1.8$ Hz, 1H, H5), 4.78 (dd, $J = 4.8, 2.6$ Hz, 1H, 2'H), 4.56 (dd, $J = 6.7, 10.5$ Hz, 1H, H7), 4.29 (d, $J = 8.3$ Hz, 1H, H20 α), 4.19 (d, $J = 8.5$ Hz, 1H, H20 β), 3.83 (d, $J = 7.0$ Hz, 1H, H3), 3.66 {t, $J = 6.7$ Hz, 6H, $\text{C}_7\text{OSi}[\text{OCH}_2(\text{CH}_2)_6\text{CH}_3]_3$ }, 3.60 (d, $J = 4.9$ Hz, 1H, $\text{C}_2'\text{OH}$), 2.64 (ddd, $J = 14.7, 9.7, 6.9$ Hz, 1H, H6 α), 2.37 (s, 3H, C_4OAc), 2.34-2.27 (m, 2H, H14 α and H14 β), 2.14 (s, 3H, C_{10}OAc), 1.97-1.90 (m, 4H, H6 β and C_{18}H_3), 1.74-1.70 (m, 4H, C_{10}OH and C_{19}H_3), 1.52 {tt, $J = 6.8, 6.8$ Hz, 6H, $\text{C}_7\text{OSi}[\text{OCH}_2\text{CH}_2(\text{CH}_2)_5\text{CH}_3]_3$ }, 1.34-1.22 {m, 33H, C_{17}H_3 and $\text{C}_7\text{OSi}[\text{OCH}_2\text{CH}_2(\text{CH}_2)_5\text{CH}_3]_3$ }, 1.16 (s, 3H, C_{16}H_3), and 0.88 {t, $J = 6.8$ Hz, 9H, $\text{C}_7\text{OSi}[\text{OCH}_2\text{CH}_2(\text{CH}_2)_5\text{CH}_3]_3$ }. ^{13}C NMR (125 MHz, CDCl_3): δ 202.2, 172.7, 170.3, 168.8, 167.2, 167.0, 140.0, 138.3, 133.93, 133.89, 132.1, 130.4, 129.4, 129.1, 128.9 (x3), 128.5, 127.3, 127.2, 84.5, 81.5, 78.8, 76.8, 76.0, 74.9, 73.3, 72.1, 63.9, 58.6, 54.9, 47.0, 43.4, 36.6, 35.6, 32.5, 32.1, 29.62, 29.57, 26.8, 25.9, 22.91, 22.88, 21.1, 21.0, 14.5, 14.3, and 10.3. HRMS (ESI) Calcd for $\text{C}_{71}\text{H}_{101}\text{NNaO}_{17}\text{Si}$ [$\text{M} + \text{Na}$] $^+$ 1290.6731; found 1290.6738.

25 **IR** (thin film) 3500 (br), 2926, 2855, 1732, 1710, 1673, 1602, 1582, 1452, 1396, 1370, 1317, 1281, 1269, 1241, 1179, 1093, 1025, 988, 968, 890, 844, 809, and 712 cm^{-1} . **mp** = 69-73 $^\circ\text{C}$. **TLC** R_f (2:1 Hexanes:EtOAc) = 0.4.

09531.308WO1 - 20110152

Example 9. Preparation of a Representative Compounds of the Invention

Using a procedure similar to the one described in Example 1, the following compounds were also prepared.

**Example 10. Release Data**

PTX silicate prodrug-loaded nanoparticles were prepared from Compounds **1a**, **1b**, **1c**, **2a**, **2b**, and **4** as described herein (10 mg of PTX) and were dispersed in 10.0 ml Phosphate buffer solution at pH=7.4 or 6.4 in dialysis cassette (MW cutoff: 10 k) and incubated in a 37°C shaker. At determined time intervals (1, 3, 6, 8 10, 24 hr), 250 μ l nanosuspension (in triplicate) was removed from each cassette and freeze dried. Freeze dried samples were redissolved in acetonitrile and extracted overnight. HPLC was used to quantify the remaining prodrug in each cassette. Data for representative compounds of formula (I) is shown in Figure 1, which shows paclitaxel silicate release data from nanoparticles. All the data points indicate silicate prodrug; Remaining% indicates the amount of prodrug that is still captured in nanoparticles in dialysis cassette.

09531.308WO1 - 20110152

Example 11. Cytotoxicity against tumor cells in vitro

Tumor cells (4T1, PANC-1 or MDA-MB-231) were seeded in 96-well plates and allowed to attach. Cells were then treated with paclitaxel (solubilized in growth medium using ethanol),
5 silicate prodrug (**2a**, solubilized in growth medium using ethanol), silicate prodrug nanoparticles (a 58:42 wt% mixture of the bis-triethyl silicate paclitaxel prodrug **2a** and a 5K-10K PEG-PLGA BCP dispersed in growth medium) or copolymer-only (blank, no drug) nanoparticles for 72 hours. Cell viability was then measured using a standard MTS assay kit (Promega). As shown in Figure 2
10 silicate prodrug and silicate prodrug nanoparticles demonstrated anticancer efficacy similar to the parent compound, paclitaxel. At the concentrations tested, blank particles did not have any effect on cell viability.

Example 12. 4T1 tumor growth in mice

15 Orthotopic 4T1 tumors were grown by injecting $\sim 1 \times 10^6$ tumor cells in the mammary fat pad of BALB/c mice. When the tumors were about 100 mm^3 in volume, the animals were injected with a single dose of paclitaxel dissolved in 1:1 mix of ethanol and cremophor (same formulation as Taxol[®]), silicate prodrug (**2a**) dissolved in 1:1 mix of ethanol and cremophor (same formulation as Taxol[®]), or silicate prodrug nanoparticles dispersed in buffered saline. Untreated animals or
20 those treated with just cremophor/ethanol vehicle were used as controls. Silicate prodrug nanoparticles resulted in greater tumor growth inhibition compared to the conventional paclitaxel treatment ($1450 \pm 65 \text{ mm}^3$ Vs $1100 \pm 99 \text{ mm}^3$ on Day 13). Importantly, animals that received paclitaxel in cremophor/ethanol had severe tissue irritation and necrosis at the site of injection, whereas those that received the nanoparticle formulation had no inflammation. This study clearly
25 indicates the benefit of formulating paclitaxel in the form of silicate prodrug nanoparticle formulation.

09531.308WO1 - 20110152

Examples 13-16

The properties and activity of a compound or a formulation of the invention can be evaluated using the assays described in Examples 13-16.

Example 13. PTX silicate hydrolysis rates.

5 A known quantity of a PTX prodrug was dissolved in 900 μL of d_6 -acetone. To this homogenous solution, 100 μL of a 9:1 solution of D_2O : trifluoroacetic acid (TFA) was added, and the solution was vigorously mixed. The ^1H NMR spectra was taken (16 transients) on a 500 MHz Varian instrument at multiple time points over the course of more than three half-lives. The study was conducted at room temperature ($\text{rt} = 22.5\text{ }^\circ\text{C} \pm 1.0\text{ }^\circ\text{C}$) Upon completion of the study, the 2' and/or 7
10 methine resonances were integrated in a baseline-adjusted NMR spectrum using MestRec software. The relative integrations were used to determine the extent of hydrolysis. The data from three replications was plotted on a semi-log scale to determine the k_{obs} of the prodrug that were then converted to the k_{rel} data as presented, defining the rate of the most slowly hydrolyzed prodrug (**1d**) as $k_{\text{rel}} = 1.0$. Errors are defined as the standard deviation of the three trials.

15 ^1H NMR spectroscopy was used to establish relative hydrolysis rates of compounds 1-3. The compounds were dissolved in a solution of d_6 -acetone, D_2O , and trifluoroacetic acid (TFA) in a 90:9:1 ratio (v/v/v). Resonances of, e.g., $\text{H}_{2'}$ in the reactant silicate vs. product carbinol were monitored. No partially hydrolyzed silicate intermediates were detected, which suggests that the initial hydrolysis event (i.e., cleavage of the first Si-OR bond) is the rate-limiting step.

20 The results (Table 1) show that increasing the steric bulk of the silicate prodrug slows its hydrolysis rate. The k_{rel} values differ by $>2000\times$ between the extremes of the triethyl PTX-silicate **1a** to the hindered di-*t*-butyl/ethyl silicate **1d**. The hydrolysis rates for **1a** and **1b** were similar (k_{rel} of ca. 3), which shows that the hydrophobicity of the silicate can be significantly increased with only a small change in the relative hydrolysis rate. As a group, prodrugs bearing the silicate at C7
25 hydrolyzed ca. 10x slower than those at C2'.

09531.308WO1 - 20110152

Table 1. Hydrolysis rates of the PTX silicate prodrugs relative to that of the slowest (**1d**).

Prodrug	at C2' k_{rel}	at C7 k_{rel}
1a	2200 ± 600	n/a
1b	710 ± 30	n/a
1c	69 ± 4	n/a
1d	1.0 ± 0.1	n/a
2a	1800 ± 100	250 ± 10 ^a
2b	460 ± 10	41 ± 3 ^b
3a	n/a	270 ± 10
3b	n/a	55 ± 3

^a The rate of hydrolysis of in situ generated **3a** to PTX.^b The rate of hydrolysis of in situ generated **3b** to PTX.**Example 14. In vitro cytotoxicity of PTX silicate prodrugs.**

MDA-MB-231 and MDA-MB-231 Luciferase positive cells were maintained independently in MEM supplemented with 1% pen/strep and 10%FBS at 37°C in a humidified incubator. MDA-MB-231 cells were obtained from the American Type Culture Collection. MDA-MB-231 Luc+ cells were obtained from CaliperLS (Hopkinton, MA, USA). For MTT cytotoxicity studies, MDA-MB-231 cells were seeded at 8,000 cells/well in a 96 well plate in 100μL MEM with 5%FBS. Paclitaxel, and paclitaxel silicate prodrug stock solutions of 10mM were prepared in DMSO. Stock solutions were diluted to 2X concentration in MEM with 5%FBS, 100μL volume, and pipetted into the 96 well plate. Concentration ranges were from 1 – 10,000nM. After 48 hours, 30μL of MTT working reagent was added to cells. Absorbance at 490nm was monitored on a 96 well plate UV vis detector at 60 minutes. IC50 values were determined by nonlinear regression analysis of log concentration v. response data obtained from the MTT assay. The IC50 was interpolated from the resulting curves using Graphpad Prism v5.1 (Graphpad Software Inc. La Jolla CA, USA).

09531.308WO1 - 20110152

Cytotoxicity of the PTX silicate prodrugs **1-3** was examined in the MDA-MB-231 human breast cancer cell line (Table 2). With the exception of the two least hydrolytically labile prodrugs (**1d** and **3b**), all of the silicates showed very similar growth inhibition properties to one another as well as to PTX itself.

Table 2. Cytotoxicity of silicate prodrugs **1-3** in MDA-MB-231 cells.^a

Compound	IC ₅₀ (nM)
PTX	23.6 (± 9.8)
1a	23.0 (± 10.7)
1b	35.6 (± 19.4)
1c	24.5 (± 12.7)
1d	8140. (± 1320)
2a	74.4 (± 35.0)
3a	21.4 (± 12.5)
3b	540. (± 113)

^a cell viability measured after 48 h.

Example 15. NP formulation of silicate **2a with PEG-b-PLGA by FNP.**

Prodrug **2a**-loaded nanoparticles were fabricated by the Confined-Impingement Jets Mixer (see Johnson BK, Prud'homme RK, *AIChE*, **2003**, 49:2264–2282). A 5K-10K PEG-b-PLGA polymer (25 mg) and prodrug **2a** (35 mg) were dissolved in THF (2.5 ml) and impinged against 2.5 ml DI water in the CIJ mixer over the course of 5 s. The resulting nanoparticle suspension, was immediately diluted in 45 mL DI water, resulting in a nanosuspension of 1.2 mg/mL in a mixture of THF and DI water (5:95). The nanosuspension was lyophilized (Freezone 4.5, Labconco) and kept frozen at -80°C for long-term storage. After freeze drying, NPs were dispersed in DI water (~ 1 mg/ml, 0.1 wt%) while cooling in an ice bath using probe sonication (Sonicator 3000, Ultrasonic liquid processor) at 20 kHz for five minutes.

09531.308WO1 - 20110152

A hallmark of the FNP process is that enables the production of stable NPs that carry much higher drug loads than is typical for more conventional polymer-based carriers. The bis-triethoxysilicate prodrug **2a** and PEG-b-PLGA (5K-10K) were formulated into nanoparticles (hereafter called **2a-NP**) by FNP. The load level of the prodrug **2a** was determined (HPLC) to be 47±5 wt% (equivalent to a 34 wt% of unfunctionalized PTX). This is unusually high for a drug delivery formulation of a member of the taxane family. DLS measurements of the **2a-NPs** showed an average hydrodynamic diameter of 120 nm (S.D. of 10 nm for nine measurements – three measurements from each of three separate formulations). The initial average size was essentially maintained for at least three days. Cryo-TEM was used to obtain more information about the nanoscopic structures of these particles. Some images show the spherical nature of **2a-NPs**, while others suggest a core-shell microstructure.

Example 16. PTX Silicate Prodrug NP Efficacy in Tumor-Bearing Animals.

The in vivo efficacy of **2a-NPs** was evaluated in mice carrying orthotopic MDA-MB-231 tumor xenografts. This cell line was stably transfected with luciferase to enable subsequent quantitative luminescence studies. The prodrug-loaded particles of **2a-NP** were prepared for administration by lyophilization to remove the organic solvent and water immediately following preparation of the initial FNP dispersion. The resulting white powder was then resuspended into a PBS solution (1 wt%, probe tip sonication) immediately prior to injection into tumor-bearing animals.

Three active PTX agents were administered (n≥5 for each group): **2a-NP**, PTX-CrEL[®] (formulated as in Taxol[®]), and Abraxane[®]. Equimolar quantities of PTX were used in each dosing regimen to enable comparison of the therapeutic response of **2a-NP** vis-à-vis the current clinical formulations of PTX. Non-drug loaded CrEL[®] and PEG-b-PLGA NP (hereafter, blank NPs) control groups were also included.

Quantitative luminescence was used to determine therapeutic response. Luciferase-catalyzed oxidation of luciferin is an ATP-dependent reaction, and the intensity of the resulting photon emission was taken to be indicative of the number of viable grafted luc+ MDA-MB-231 cells at the primary tumor site. The data in Figure 5 summarize the luminescence response from all animals in

09531.308WO1 - 20110152

a given test group at the indicated time points. Highlights are that each of the **2a-NP**, PTX-CrEL[®], and Abraxane[®] treatment groups showed significant inhibition of tumor growth relative to the control groups and that all three of **2a-NP**, PTX-CrEL[®], and Abraxane[®] were statistically comparable in their protective capacity. It is important to restate that the dosage of PTX or PTX prodrug was identical (50 $\mu\text{mol kg}^{-1}$) for all treatment groups and that, because the wt% of prodrug in **2a-NP** (47 ± 5 wt%) was considerably higher than that of PTX in PTX-CrEL[®] (1.1%) or Abraxane[®] (10%), much lower amounts of excipient were administered to the animals receiving **2a-NPs**. The data also suggest that tumors in mice treated with **2a-NPs** were decellularized (i.e., less dense at the tumor core) relative to Abraxane[®]- and PTX-CrEL[®]-treated mice. Histologic assessment of tumors at the study endpoint revealed a central necrotic/apoptotic core in all PTX treatment groups. Hematoxylin and eosin (H&E) staining of tumors showed an outer rim of mitotically active cells with a large central core that stained positive for caspase-3, a marker for apoptosis. A trend towards a larger central non-viable core was observed in the **2a-NP** group relative to the PTX-CrEL[®] and Abraxane[®] treatment groups, thus providing additional evidence for greater decellularization of tumors in mice treated with **2a-NPs**.

Upon conclusion of the luminescence study, the toxicological profile was determined for the **2a-NP**, PTX-CrEL[®], and Abraxane[®] treatment groups (Table 3). Qualitatively, tail tissue near the injection site in the CrEL[®]- and PTX-CrEL[®]-treated mice were found to exhibit necrotic characteristics, suggesting significant toxic side effects from the CrEL[®] excipient. Plasma solute assay and enzymology were used to assess hepatotoxicity. Notably, in Abraxane[®]-treated mice, mean aspartate transaminase (AST) and alanine transaminase (ALT) levels were above normal (vs. Balb/c nude mice), suggesting potentially greater liver damage. Lymphocytopenia was noted in both the Abraxane[®] and PTX-CrEL[®] groups, while values for **2a-NP**-treated mice fell within the normal range. The absence of hematological or liver toxicity are encouraging and consistent with the idea that **2a-NP** provides lower levels of toxic agent over a longer duration by virtue of slow release of PTX, thereby leading to a better safety profile, while maintaining equivalent efficacy to current clinical formulations.

09531.308WO1 - 20110152

Table 3. Selected toxicological profile data for PTX-CrEL[®], Abraxane[®], and **2a-NP** groups.

Treatment	ALT (U/L)	AST (U/L)	Mean Cell Hemoglobin (g•dL ⁻¹)	Lymphocytes (%)	Neutrophils (%)
Expected	51.3 (± 18.8)	119.4 (± 95.5)	30.4 (± 2.7)	62.5 (± 10.3)	29.9 (± 8.4)
Untreated	27.3 (± 6.3)	194.2 (± 71.2)			
2a-NP	24.3 (± 9.0)	123.6 (± 61.1)	27.6 (± 0.6)	59.7 (± 16.2)	32.0 (± 13.0)
PTX-CrEL [®]	27.2 (± 3.8)	170.0 (± 69.2)	27.9 (± 3.3)	43.7 (± 5.0)	46.7 (± 2.1)
Abraxane [®]	89.0 (± 79.2)	361.6 (± 187.8)	30.5 (± 1.7)	46.0 (± 21.1)	49.0 (± 23.5)

The efficacy of a new class of PTX silicate prodrugs has been established. The strategy relies upon the ability to control both the hydrophobicity and the hydrolysis rate of these prodrugs. Each of these features provides a mechanism for enhancing drug encapsulation and release properties when the prodrugs are encapsulated in nanoparticles. Rates of hydrolysis of the prodrugs via ¹H NMR spectroscopic analysis were determined. Cytotoxicity studies were performed. Prodrugs **1a-c**, **2a**, and **3a** all showed IC₅₀ values similar to that of the parent PTX. Silicate prodrug **2a** was formulated via FNP to provide nanoparticles **2a-NP**, which contained very with high levels (47 ± 5 wt%) of prodrug load. Cryoscopic transmission electron microscopy suggested a core-shell nature for these particles. Tumor-bearing mouse models were dosed with three taxane-containing agents, and quantitative luminescence was used to assess comparative in vivo antitumor efficacy. The **2a-NPs** were found to display similar effectiveness as the clinically used formulations PTX-CrEL[®] and Abraxane[®]. Importantly, liver and blood toxicology and histology studies showed that the **2a-NP** treatment group demonstrated minimal toxicity. Notably, the amount of excipient used in the **2a-NP** formulations is significantly lower than that in the PTX-CrEL[®] and Abraxane[®] drugs.

09531.308WO1 - 20110152

Example 17. The following illustrate representative pharmaceutical dosage forms, containing a compound of the invention ('Compound X'), for therapeutic or prophylactic use in humans.

	<u>(i) Tablet 1</u>	<u>mg/tablet</u>
5	Compound X= 100.0	
	Lactose	77.5
	Povidone	15.0
	Croscarmellose sodium	12.0
	Microcrystalline cellulose	92.5
10	Magnesium stearate	<u>3.0</u>
		300.0
	<u>(ii) Tablet 2</u>	<u>mg/tablet</u>
	Compound X= 20.0	
15	Microcrystalline cellulose	410.0
	Starch	50.0
	Sodium starch glycolate	15.0
	Magnesium stearate	<u>5.0</u>
		500.0
20	<u>(iii) Capsule</u>	<u>mg/capsule</u>
	Compound X= 10.0	
	Colloidal silicon dioxide	1.5
	Lactose	465.5
25	Pregelatinized starch	120.0
	Magnesium stearate	<u>3.0</u>
		600.0
	<u>(iv) Aerosol</u>	<u>mg/can</u>
30	Compound X= 20.0	
	Oleic acid	10.0
	Trichloromonofluoromethane	5,000.0
	Dichlorodifluoromethane	10,000.0
	Dichlorotetrafluoroethane	5,000.0

35

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art.

All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that

40

09531.308WO1 - 20110152


many variations and modifications may be made while remaining within the spirit and scope of the invention.

09531.308WO1 - 20110152

CLAIMS

What is claimed is:

1. A compound comprising a taxane linked to one or more groups of formula (I):



wherein:

each R is indepently selected from (C₁-C₂₀)alkyl, (C₂-C₂₀)alkenyl, (C₂-C₂₀)alkynyl, (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, and (C₂-C₂₀)alkynylcarbonyl, wherein each (C₁-C₂₀)alkyl, (C₂-C₂₀)alkenyl, (C₂-C₂₀)alkynyl, (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, and (C₂-C₂₀)alkynylcarbonyl, is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl;

or a salt thereof.


2. The compound of claim 1 wherein an oxygen of a hydroxy group of the taxane is linked to the group of formula (I).
3. The compound of claim 1 wherein oxygens of at least two hydroxy groups of the taxane are linked to groups of formula (I).
4. The compound of any one of claims 1-3 wherein each R is independently selected from (C₁-C₂₀)alkyl, (C₂-C₂₀)alkenyl, and (C₂-C₂₀)alkynyl, wherein each (C₁-C₂₀)alkyl, (C₂-C₂₀)alkenyl, and (C₂-C₂₀)alkynyl is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl.
5. The compound of any one of claims 1-3 wherein each R is independently selected from (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, (C₂-C₂₀)alkynylcarbonyl, wherein each (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, and (C₂-C₂₀)alkynylcarbonyl, is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl.

09531.308WO1 - 20110152

6. The compound of any one of claims 1-3 wherein at least one R is independently selected from (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, (C₂-C₂₀)alkynylcarbonyl, wherein each (C₁-C₂₀)alkanoyl, (C₂-C₂₀)alkenylcarbonyl, and (C₂-C₂₀)alkynylcarbonyl, is optionally substituted with one or more hydroxy, (C₁-C₆)alkoxy, oxo, halo, or aryl.


7. The compound of any one of claims 1 and 4-6 wherein the taxane is a paclitaxel or docetaxel.

8. The compound of any one of claims 1 and 4-6 which is a compound of formula (Ia):



wherein R¹ is a group of formula (I), or a salt thereof.


9. The compound of any one of claims 1 and 4-6 which is a compound of formula (Ib):



wherein R¹ and R² are each independently a group of formula (I), or a salt thereof.


09531.308WO1 - 20110152

10. The compound of any one of claims 1 and 4-6 which is a compound of formula (Ic):



wherein R^3 is a group of formula (I), or a salt thereof.







11. The compound of any one of claims 1 and 4-6 which is a compound of formula (Id):






wherein R^2 is a group of formula (I), or a salt thereof.

09531.308WO1 - 20110152


12. The compound of claim 1 which is selected from:



09531.308WO1 - 20110152





and








and salts thereof.


13. The compound of claim 1 which is selected from:



09531.308WO1 - 20110152

**1c****1d****2a****2b****3a**

and

**3b**

and salts thereof.

09531.308WO1 - 20110152

14. A composition comprising a compound as described in any one of claims 1-13 and a PEG-*b*-PLGA block co-polymer.
15. A composition comprising a compound as described in any one of claims 1-13 and a pharmaceutically acceptable carrier.
16. The composition of claim 15 that comprises two or more compounds as described in any one of claims 1-13.
17. The composition of claim 15 or 16 that further comprises one or more additional therapeutic agents.
18. The composition of claim 17 wherein the one or more additional therapeutic agents are selected from all-trans retinoic acid, Azacitidine, Azathioprine, Bleomycin, Bortezomib, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Etoposide, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Teniposide, Tioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine, Vinorelbine, and selective and non-selective tyrosine kinase inhibitors (e.g. lapatinib, dasatinib, vemurafenib, imatinib, gefitinib, erlotinib, and sunitinib, etc.).
19. The composition of claim 17 wherein the one or more additional therapeutic agents are selected from P-gp inhibitors (verapamil, cyclosporine, tariquidar, elacridar, etc) and CYP3A4 inhibitors (ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, bergamottin, cimetidine, voriconazole, fluoxetine/norfluoxetine, piperine, and silibinin, quercetin, etc).
20. A nano-particle comprising a compound as described in any one of claims 1-13 and a PEG-*b*-PLGA block co-polymer.

09531.308WO1 - 20110152

21. A nano-particle comprising two or more different compounds as described in any one of claims 1-13.
22. A nano-particle comprising a compound as described in any one of claims 1-13 and one or more additional therapeutic agents.
23. The nano-particle of claim 22 wherein the one or more additional therapeutic agents are selected from all-trans retinoic acid, Azacitidine, Azathioprine, Bleomycin, Bortezomib, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Etoposide, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Teniposide, Tioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine, Vinorelbine, and selective and non-selective tyrosine kinase inhibitors (e.g. lapatinib, dasatinib, vemurafenib, imatinib, gefitinib, erlotinib, and sunitinib, etc.).
24. The nano-particle of claim 22 wherein the one or more additional therapeutic agents are selected from P-gp inhibitors (verapamil, cyclosporine, tariquidar, elacridar, etc) and CYP3A4 inhibitors (ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, bergamottin, cimetidine, voriconazole, fluoxetine/norfluoxetine, piperine, and silibinin, quercetin, etc).
25. A nano-particle comprising a compound as described in any one of claims 1-13 and one or more targeting moieties.
26. The nano-particle of claim 25 wherein the targeting moiety is selected from folic acid, biotin, a Cys-Arg-Glu-Lys-Ala (CREKA) peptide, mannose 6-phosphate, transferrin, a peptide targeting transferrin receptor, an epidermal growth factor receptor (EGFR) targeting peptide, an scFv or antibody, a CD133 targeting scFv or antibody, and peptides targeting the integrin receptors.

09531.308WO1 - 20110152

27. The nano-particle of claim 25 wherein the targeting moiety is selected from TRAIL, Cetuximab, Trastuzumab, Bevacizumab, Rituximab, Ibritumomab, Tositumomab, Alemtuzumab, and Epratuzumab.
28. A method to treat cancer in an animal comprising administering to the animal a compound as described in any one of claims 1-13 or a composition as described in any one of claims 14-15, or a nano-particle as described in any one of claims 20-27.
29. The method of claim 28 wherein the animal is a human.
30. A compound as described in any one of claims 1-13 or a composition as described in any one of claims 14-19, or a nano-particle as described in any one of claims 20-27 for use in medical therapy.
31. A compound as described in any one of claims 1-13 or a composition as described in any one of claims 14-18, or a nano-particle as described in any one of claims 20-27 for the prophylactic or therapeutic treatment of cancer.
32. The use of a compound as described in any one of claims 1-13 or a composition as described in any one of claims 14-18, or a nano-particle as described in any one of claims 20-27 to prepare a medicament for treating cancer in an animal.
33. A method to treat restenosis in an animal comprising administering to the animal a compound as described in any one of claims 1-13 or a composition as described in any one of claims 14-15, or a nano-particle as described in any one of claims 20-27.
34. A compound as described in any one of claims 1-13 or a composition as described in any one of claims 14-15, or a nano-particle as described in any one of claims 20-27 for use in the prophylactic or therapeutic treatment of restenosis.

09531.308WO1 - 20110152

35. The use of a compound as described in any one of claims 1-13 or a composition as described in any one of claims 14-15, or a nano-particle as described in any one of claims 20-27 to prepare a medicament for treating restenosis in an animal.
36. A method to treat cancer in an animal comprising administering to the animal two or more different compounds as described in any one of claims 1-13.
37. A method to treat cancer in an animal comprising administering to the animal a formulation that comprises two or more different compounds as described in any one of claims 1-13.
38. A method to treat cancer in an animal, comprising administering to the animal a nano-particle as described in any one of claims 20-27.
39. A method to treat cancer in an animal, comprising administering to the animal a first nano-particle that comprises one compound as described in any one of claims 1-13 and a second nano-particle that comprises a different compound any one of claims 1-13.
40. A method to treat cancer in an animal comprising administering to the animal a compound as described in any one of claims 1-13, or a formulation as described in any one of claims 14-15, or a nano-particle as described in claim 16 in combination with one or more additional therapeutic agents.
41. The method of claim 40 wherein the one or more additional therapeutic agents are selected from all-trans retinoic acid, Azacitidine, Azathioprine, Bleomycin, Bortezomib, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Etoposide, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Teniposide, Tioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine, Vinorelbine, and selective and non-selective tyrosine kinase inhibitors (e.g. lapatinib, dasatinib, vemurafinib, imatinib, gefitinib, erlotinib, and sunitinib, etc.).

09531.308WO1 - 20110152

42. The method of claim 40 wherein the one or more additional therapeutic agents are selected from P-gp inhibitors (verapamil, cyclosporine, tariquidar, elacridar, etc) and CYP3A4 inhibitors (ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, bergamottin, cimetidine, voriconazole, fluoxetine/norfluoxetine, piperine, and silibinin, quercetin, etc).

Figure 1




Figure 2




Figure 3






Figure 4



Synthesis of the silicate prodrugs of PTX. Conditions: (a) $\text{SiCl}(\text{OR}^1)_3$, NEt_3 , THF. (b) i) $\text{SiCl}_2(\text{O}^t\text{Bu})_2$, py, THF; ii) EtOH, py. (c) $\text{SiCl}(\text{OR})_3$, py, THF. (d) d_6 -acetone, D_2O , TFA (90:9:1 v/v/v). Yields of chromatographed product: **1a** (91%); **1b** (81%); **1c** (65%); **1d** (84%); **2a** (85%); **2b** (77%); **3a** (91%, brsm); and **3b** (66%, brsm). brsm = based on recovered starting material.

Figure 5

5



Mean luminescence quantitation. Photon intensity from the primary tumor site was determined for ≥ 4 mice at each time point. CrEL® and blank NP groups are shown up to the time point preceding euthanasia or death of a majority of the group. "x" indicates too few surviving animals for meaningful data interpretation. Data are presented as mean $\pm$ S.D.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/40247

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(8) - A01N 43/04; A61K 31/715 (2012.01)
 USPC - 514/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 USPC - 514/54

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 USPC - 514/4.8; 548/452 (see search terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 PubWest, Google Patents, Google Scholar, WIPO (silicate, ester, formula, taxane, prodrug, hydroxy, silica, oxide, nanoparticles, microspheres, organosilane, derivative, paclitaxel, docetaxel, alkoxy)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2009/141738 A2 (CULLIS et al.) 26 November 2009 (26.11.2009) para [0075], [0083]-[0086], [0090], [0109], [0113], [0116]-[0117]	1-6, 12-13
Y	US 2010/014650 A1 (LEE et al.) 29 April 2010 (29.04.2010) para [0002], [0005], [0012]-[0019].	1-6, 12-13
Y	US 2011/0123466 A1 (DESIMONE et al.) 26 May 2011 (26.05.2011) para [0003], [0063], [0128]	5-6

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

04 August 2012 (04.08.2012)

Date of mailing of the international search report

26 SEP 2012

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, Virginia 22313-1450
 Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/40247

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 7-11 and 14-42
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.